Contact
searchSearch
HMP Global
Login

Multiple Myeloma

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Sikander Ailawadhi, MD
Videos
FDA Approval Expands Isatuximab Delivery Options in Multiple Myeloma
08/07/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD,...
08/07/2026
Oncology
Peter Voorhees, MD
Videos
MonumenTAL-3 Demonstrates Superior Outcomes With Talquetamab-Based Combinations in Relapsed Multiple Myeloma
07/15/2026
Peter Voorhees, MD
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses...
07/15/2026
Oncology
Binod Dhakal, MD
Videos
Allogeneic BCMA CAR T-Cell Therapy Demonstrates Durable Activity and Manageable Safety in Relapsed or Refractory Multiple Myeloma
06/23/2026
Binod Dhakal, MD
Binod Dhakal, MD, discusses results from the phase 1 CaMMouflage trial supporting the use of the allogeneic BCMA-directed CAR T-cell therapy CB-011 as a potentially scalable off-the-shelf treatment option for patients with relapsed or...
Binod Dhakal, MD, discusses results from the phase 1 CaMMouflage trial supporting the use of the allogeneic BCMA-directed CAR T-cell therapy CB-011 as a potentially scalable off-the-shelf treatment option for patients with relapsed or...
Binod Dhakal, MD, discusses...
06/23/2026
Oncology
Saurabh Chhabra, MD
Videos
Etentamig Demonstrates Durable Activity Following Prior BCMA Therapy in Multiple Myeloma
06/23/2026
Saurabh Chhabra, MD
Saurabh Chhabra, MD, discusses results from the phase 1b MONVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses results from the phase 1b MONVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses...
06/23/2026
Oncology
Roberto Mina, MD
Videos
MajesTEC-9 Establishes Teclistamab as a New Standard in Early Relapsed or Refractory Multiple Myeloma
06/23/2026
Roberto Mina, MD
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial showing that teclistamab significantly improved progression-free survival, overall survival, complete response rates, and MRD negativity compared with standard-of-care...
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial showing that teclistamab significantly improved progression-free survival, overall survival, complete response rates, and MRD negativity compared with standard-of-care...
Roberto Mina, MD, discusses...
06/23/2026
Oncology
Peter Frosberg, MD
Videos
Feasibility of Community-Based Outpatient Bispecific Therapy in Multiple Myeloma
06/19/2026
Peter Forsberg, MD
Peter Forsberg, MD, discusses results from the phase 2 OPTEC trial showing that prophylactic tocilizumab reduced cytokine release syndrome rates to 5% with teclistamab and 14% with talquetamab while maintaining strong efficacy and enabling...
Peter Forsberg, MD, discusses results from the phase 2 OPTEC trial showing that prophylactic tocilizumab reduced cytokine release syndrome rates to 5% with teclistamab and 14% with talquetamab while maintaining strong efficacy and enabling...
Peter Forsberg, MD, discusses...
06/19/2026
Oncology
Sikander Ailawadhi, MD
Videos
Isatuximab Retreatment After Prior Anti-CD38 Therapy in Relapsed or Refractory Multiple Myeloma
06/19/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses post hoc analysis results from the phase 3 IRAKLIA trial showing that isatuximab plus pomalidomide and dexamethasone retained meaningful clinical activity in patients with relapsed or refractory multiple...
Sikander Ailawadhi, MD, discusses post hoc analysis results from the phase 3 IRAKLIA trial showing that isatuximab plus pomalidomide and dexamethasone retained meaningful clinical activity in patients with relapsed or refractory multiple...
Sikander Ailawadhi, MD,...
06/19/2026
Oncology
Enrique Ocio, MD, PhD
Videos
DREAMM-9 Final Analysis Shows Strong Efficacy With Belantamab Mafodotin Plus VRd in Newly Diagnosed Multiple Myeloma
06/16/2026
Enrique Ocio, MD, PhD
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses...
06/16/2026
Oncology
Roberto Mina, MD
Videos
Teclistamab Monotherapy Improves Outcomes in Patients With Relapsed or Refractory Multiple Myeloma
06/16/2026
Roberto Mina, MD
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy in patients with relapsed or refractory multiple myeloma.
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy in patients with relapsed or refractory multiple myeloma.
Roberto Mina, MD, discusses...
06/16/2026
Oncology
Omar Nadeem, MD
Videos
Teclistamab Achieves Deep MRD-Negative Responses in High-Risk Smoldering Myeloma
06/15/2026
Omar Nadeem, MD
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM showing that teclistamab produced substantially higher complete response, MRD negativity, and progression-free survival rates than lenalidomide plus dexamethasone in patients...
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM showing that teclistamab produced substantially higher complete response, MRD negativity, and progression-free survival rates than lenalidomide plus dexamethasone in patients...
Omar Nadeem, MD, discusses...
06/15/2026
Oncology

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use